The relationship between plasma D-lactate level and small intestinal damage in patients taking aspirin

doi:10.3969/j.issn.1006-7795.2021.05.018

Abstract

Abstract: Objective To investigate the relationship between plasma D-lactate level and small intestinal damage in patients taking aspirin. Methods From May 2019 to December 2019, 106 patients who had been taking aspirin for over one month in Beijing Anzhen Hospital, Capital Medical University were enrolled. They were examined by magnetically controlled capsule endoscopy. According to the five-point scoring system for endoscopic lesions with capsule endoscopy, patients with normal small intestinal mucosa were divided into the normal group, those with erythema or 1-4 small erosions were divided into the mild damage group, and those with more than 4 small erosions or large erosions/ulcers were divided into the major damage group. The expression levels of plasma D-lactate and inflammatory factors interleukin-1β(IL-1β), tumor necrosis factor (TNF-α), interleukin-10(IL-10) were detected by colorimetry and enzyme-linked immunosorbent assay, respectively. The efficacy of D-lactate in the diagnosis of severe small intestinal damage was evaluated by receiver operating characteristic(ROC) curve. Results Among the 106 patients taking aspirin, 14 cases were in the normal group, 74 cases were in the mild damage group and 18 cases were in the major damage group. The plasma D-lactate levels of the three groups were 106.59 (70.17, 278.11) nmol/mL, 167.19 (31.81, 439.57) nmol/mL and 349.88 (182.23, 1 442.5) nmol/mL, there was significant difference among the three groups (P=0.022). The area under ROC curve was 0.704 (95% CI: 0.572-0.836, P=0.006). The level of D-lactate (754.15 nmol/mL) corresponding to the maximum point of Youden index was taken as the cut-off point. When D-lactate level≥754.15 nmol/ml, the sensitivity, specificity and kappa were 44.4%, 90.9% and Kappa=0.370, respectively,the predicted effect was poor. Conclusion The levels of plasma D-lactate varies with the degree of small intestinal damage in patients taking aspirin. However, the effect of plasma D-lactate level in predicting aspirin related severe small intestinal damage is not ideal.

Key words: D-lactate, small intestinal damage, aspirin, inflammatory factors

CLC Number:

Chen Xue, Gao Feng, Zhang Jie. The relationship between plasma D-lactate level and small intestinal damage in patients taking aspirin[J]. Journal of Capital Medical University, 2021, 42(5): 810-815.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2021.05.018

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2021/V42/I5/810

References

[1] 中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2019概要[J]. 中国循环杂志, 2020, 35(9): 833-854.
[2] Gao F, Chen X, Zhang J. Prevalence of gastric and small-intestinal mucosal injury in elderly patients taking enteric-coated aspirin by magnetically controlled capsule endoscopy[J]. Gastroenterol Res Pract, 2019, 2019: 1582590.
[3] Handa O, Takayama S, Mukai R, et al. A review of the mechanism and prophylaxis of acetyl salicylic acid-induced injury of the small intestine[J]. Free Radic Res, 2018, 52(11-12): 1266-1270.
[4] 唐凯,周新妹,吴长明,等. 血浆D-乳酸对非甾体抗炎药相关肠黏膜损害的早期诊断探讨[J]. 浙江临床医学, 2016, 18(11): 1975-1977.
[5] Svedlund J, Sjodin I, Dotevall G. GSRS-a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease[J]. Dig Dis Sci, 1988, 33(2): 129-134.
[6] 中国医师协会内镜医师分会消化内镜专业委员会,中国医师协会内镜医师分会消化内镜健康管理与体检专业委员会,中华医学会消化内镜分会胶囊内镜协作组,等. 中国磁控胶囊胃镜临床应用专家共识(2017年,上海)[J]. 中华内科杂志, 2017, 56(11): 876-884.
[7] Graham D Y, Opekun A R, Willingham F F, et al. Visible small-intestinal mucosal injury in chronic NSAID users[J]. Clin Gastroenterol Hepatol, 2005, 3(1): 55-59.
[8] 左惠娟,邓利群.阿司匹林在心血管疾病一级和二级预防中的应用现状分析[J].心肺血管病杂志,2018,37(11):953-958, 979.
[9] Endo H, Sakai E, Kato T, et al. Small bowel injury in low-dose aspirin users[J]. J Gastroenterol, 2015(4), 50:378-386.
[10]Watari I, Oka S, Tanaka S, et al. Comparison of small-bowel mucosal injury between low-dose aspirin and non-aspirin non-steroidal anti-inflammatory drugs: a capsule endoscopy study[J]. Digestion, 2014, 89(3): 225-231.
[11]Wallace J L. Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy[J]. World J Gastroenterol, 2013, 19(12): 1861-1876.
[12]Smith S M, Eng R H, Buccini F. Use of D-lactic acid measurements in the diagnosis of bacterial infections[J]. J Infect Dis, 1986, 154(4): 658-664.
[13]Levitt M D, Levitt D G. Quantitative evaluation of D-lactate pathophysiology: new insights into the mechanisms involved and the many areas in need of further investigation[J]. Clin Exp Gastroenterol, 2020, 13: 321-337.
[14]Hu J S, Huang Y Y, Kuang J H, et al. Streptococcus thermophiles DMST-H2 promotes recovery in mice with antibiotic-associated diarrhea[J]. Microorganisms, 2020, 8(11): 1650.
[15]Yin J, Wang S, Qiu Y, et al. Screening for and combining serum intestinal barrier-related biomarkers to predict the disease severity of AECOPD[J]. Ann Palliat Med, 2020, 10(2):1548-1559.
[16]Otani K, Tanigawa T, Watanabe T, et al. Microbiota plays a key role in non-steroidal anti-inflammatory drug-induced small intestinal damage[J]. Digestion, 2017, 95(1): 22-28.
[17]Xiao X, Nakatsu G, Jin Y, et al. Gut microbiota mediates protection against enteropathy induced by indomethacin[J]. Sci Rep, 2017, 7: 40317.
[18]Chen X, Gao F, Zhang J. Screening for gastric and small intestinal mucosal injury with magnetically controlled capsule endoscopy in asymptomatic patients taking enteric-coated aspirin[J]. Gastroenterol Res Pract, 2018, 2018: 2524698.
[19]Washio E, Esaki M, Maehata Y, et al. Proton pump inhibitors increase incidence of nonsteroidal anti-inflammatory drug-induced small bowel injury: a randomized, placebo-controlled trial[J]. Clin Gastroenterol Hepatol, 2016, 14(6): 809-815.
[20]Cai J, Chen H, Weng M, et al. Diagnostic and clinical significance of serum levels of D-lactate and diamine oxidase in patients with Crohn's disease[J]. Gastroenterol Res Pract, 2019, 2019: 8536952.